Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

Sponsor
Assiut University
Study ID
NCT05950542
Status
Unknown

Conditions

  • Vitiligo, Generalized

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The study aims to evaluate the safety and efficacy of the combination of topical baricitinib and 308-nm monochromatic excimer light versus 308-nm monochromatic excimer light alone in treatment of non-segmental vitiligo.

Key Dates

First listed
Jul 18, 2023
Start date
Sep 10, 2023
Status verified
Jul 2023
Primary completion
Sep 20, 2024
Completion
Dec 30, 2024

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Group A
    Vitiligo lesions on the face will be treated with cream (Olumiant)2mg twice daily and excimer light308nm DEKA, Florence,Italy twice weekly for 12 weeks.
  • Arm: Group B
    Vitiligo lesions on the face will be treated with excimer light308nm (DEKA,F lorence,Italy) only twice weekly for 12 weeks.

Primary Outcome Measure

F VASI score [ Time Frame: 6 months ]

Central Contacts